[1]胡雨平,叶民珠.左西孟旦对经皮冠状动脉介入术后患者心脏储备功能及无复流心力衰竭风险的影响[J].医学信息,2022,35(23):125-128.[doi:10.3969/j.issn.1006-1959.2022.23.025]
　HU Yu-ping,YE Min-zhu.Effect of Levosimendan on Cardiac Reserve Function and Risk of No-reflow Heart Failure in Patients After Percutaneous Coronary Intervention[J].Journal of Medical Information,2022,35(23):125-128.[doi:10.3969/j.issn.1006-1959.2022.23.025]
点击复制

左西孟旦对经皮冠状动脉介入术后患者心脏储备功能及无复流心力衰竭风险的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
125-128
栏目:
药物与临床
出版日期:
2022-12-01

文章信息/Info

Title:
Effect of Levosimendan on Cardiac Reserve Function and Risk of No-reflow Heart Failure in Patients After Percutaneous Coronary Intervention
文章编号:
1006-1959（2022）23-0125-04
作者:
胡雨平; 叶民珠
（赣县区人民医院心血管内科，江西 赣州 341100）
Author(s):
HU Yu-ping; YE Min-zhu
(Department of Cardiovascular Medicine,Ganxian District People’s Hospital,Ganzhou 341100,Jiangxi,China)
关键词:
经皮冠状动脉介入术; 左西孟旦; 心脏储备功能; 无复流心力衰竭; 肾功能
Keywords:
Percutaneous coronary intervention; Levosimendan; Cardiac reserve function; No-reflow heart failure; Renal function
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2022.23.025
文献标志码:
A
摘要:
目的 研究左西孟旦对经皮冠状动脉介入术（PCI）后患者心脏储备功能及无复流心力衰竭风险的影响。方法 选取2019年8月-2021年7月于赣县区人民医院行PCI治疗的68例患者，按照随机数字表法分为对照组与观察组，各34例。对照组给予常规治疗，观察组则在对照组基础上给予左西孟旦治疗，比较两组临床疗效、心脏储备功能[左心室射血分数（LVEF）、左室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）]、炎症因子[超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、细胞间黏附分子-1（ICAM-1）]、肾功能指标[血肌酐（Scr）、血尿素氮（BUN）]、主要不良心血管事件（MACE）发生率。结果 观察组治疗总有效率为94.12%，高于对照组的82.35%（P＜0.05）；观察组LVEF高于对照组，LVEDD、LVESD低于对照组（P＜0.05）；观察组hs-CRP、TNF-α、ICAM-1水平低于对照组（P＜0.05）；观察组Scr、BUN水平低于对照组（P＜0.05）；观察组MACE发生率为5.88%，低于对照组的20.59%（P＜0.05）。结论 左西孟旦可提高PCI患者临床疗效，改善其心脏储备功能，下调炎性指标，同时缓解肾功能损害，降低无复流心力衰竭等不良心血管事件的发生风险。
Abstract:
Objective To study the effect of levosimendan on cardiac reserve function and risk of no-reflow heart failure in patients after percutaneous coronary intervention (PCI).Methods A total of 68 patients who underwent PCI in Ganxian District People’s Hospital from August 2019 to July 2021 were selected and divided into control group and observation group according to random number table method, with 34 cases in each group. The control group was given routine treatment, while the observation group was treated with levosimendan on the basis of the control group. The clinical efficacy, cardiac reserve function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD)], inflammatory factors [high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), intercellular adhesion molecule-1 (ICAM-1)], renal function indexes [serum creatinine (Scr), blood urea nitrogen (BUN)], incidence of major adverse cardiovascular (MACE) were compared between the two groups.Results The total effective rate of the observation group was 94.12%, which was higher than 82.35% of the control group (P<0.05). LVEF in the observation group was higher than that in the control group, LVEDD and LVESD were lower than those in the control group (P<0.05). The levels of hs-CRP, TNF-α and ICAM-1 in the observation group were lower than those in the control group (P<0.05). The levels of Scr and BUN in the observation group were lower than those in the control group (P<0.05). The incidence of MACE in observation group was 5.88%, which was lower than 20.59% in control group (P<0.05).Conclusion Levosimendan can improve the clinical efficacy of PCI patients, improve their cardiac reserve function, down-regulate inflammatory indicators, alleviate renal function damage, and reduce the risk of adverse cardiovascular events such as no-reflow heart failure.

参考文献/References:

[1]Joo HJ,Ahn SG,Park JH,et al.Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study[J].Scientific Reports,2018,8(1):1229.[2]郝国贞,高恒波,范卫泽,等.左西孟旦治疗老年慢性心力衰竭的效果与安全性评价[J].中国全科医学,2015,18(26):3153-3157.[3]赵琳,马玉茹,马芸芸.PCI后心力衰竭患者左西孟旦治疗的临床疗效和潜在机制探讨[J].临床心血管病杂志,2020,36(11):1048-1052.[4]李凤玲,马林,程林.左西孟旦对急性ST段抬高型心肌梗死并急性心力衰竭患者QT离散度及室性心律失常的影响[J].中国实用医刊,2020,47(9):114-117.[5]吴刚,周宇.左西孟旦对老年慢性心力衰竭心室重构及相关指标的影响[J].中华老年心脑血管病杂志,2020,22(4):393-396.[6]张远生,陈磊,陈跃武.左西孟旦对急性心肌梗死患者PCI术后肾功能的影响[J].解放军预防医学杂志,2019,37(8):120-121,124.[7]Prati F,Romagnoli E,La Manna A,et al.Long-term consequences of optical coherence tomography findings during percutaneous coronary intervention: the Centro Per La Lotta Contro L’infarto - Optimization Of Percutaneous Coronary Intervention (CLI-OPCI) LATE study[J].EuroIntervention,2018,14(4):e443-e451.[8]武星君,官庆妮,杨红萍,等.左西孟旦对急性心力衰竭病人心功能及血清BNP,IL-6,TNF-α,hs-CRP水平的影响[J].中西医结合心脑血管病杂志,2018,16(3):326-329.[9]宗雪梅,李兵强,王耀辉,等.左西孟旦在缺血性心力衰竭患者PCI术中的应用价值[J].河南医学研究,2017,26(22):4050-4052.[10]胡燕雄.急性心肌梗死患者PCI术后应用左西孟旦与重组人脑利钠肽疗效[J].牡丹江医学院学报,2017,38(5):49-52.[11]王保才,葛振伟,程兆云,等.左西孟旦治疗急性失代偿心力衰竭疗效及对患者BNP、CRP、IL-6水平的影响[J].中国医院药学杂志,2017,37(20):2081-2084.[12]王洪云,赵拥军,秦亮.左西孟旦对急性心肌梗死后左心衰竭患者心功能、血压及心率的影响[J].滨州医学院学报,2017,40(4):259-262.[13]李兵强,王耀辉,宗雪梅,等.左西孟旦在行经皮冠状动脉介入治疗缺血性心力衰竭中的应用[J].中国综合临床,2017,33(9):807-811.[14]付文科,孙玉发,郝卫军,等.左西孟旦治疗老年缺血性心肌病所致急性失代偿性心力衰竭的疗效和安全性分析[J].中华老年心脑血管病杂志,2017,19(2):153-155.[15]张春晓,陈玉东.左西孟旦与重组人脑利钠肽治疗AMI急诊PCI术后患者短期临床疗效的对比[J].临床心血管病杂志,2017,33(1):39-43.[16]王磊.左西孟旦、米力农与多巴酚丁胺治疗急性失代偿心力衰竭患者临床疗效及安全性评价[J].药物评价研究,2017,40(1):92-95.[17]李丽丽,刘辉,董志,等.左西孟旦治疗急性心力衰竭患者的效果及其对血清脑钠肽的影响[J].疑难病杂志,2016,15(8):787-790.[18]Bouchez S,Fedele F,Giannakoulas G,et al.Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application[J].Cardiovasc Drugs Ther,2018,32(6):617-624.[19]张东伟,康艳霞,闫文俊,等.早期应用左西孟旦对急性前壁心肌梗死伴心功能不全行急诊PCI治疗患者的疗效观察[J].贵州医药,2016,40(3):261-262.[20]吴淑彬,丁力平,靳志涛,等.左西孟旦与重组人脑利钠肽治疗急性失代偿性心力衰竭效果对比研究[J].天津医药,2016,44(6):789-792.[21]宋维鹏,国强华,贾红丹,等.左西孟旦对老年急性心肌梗死合并心衰患者心功能及hs-CRP、IL-6、TNF-α水平的影响[J].海南医学院学报,2016,22(12):1264-1266,1269.[22]王紫监,陈敏,张海洋,等.左西孟旦对经皮冠状动脉介入术后患者心脏功能的影响及预防无复流心力衰竭的价值研究[J].中国临床医生杂志,2021,49(7):794-797.[23]魏峰,郑若龙,李伟章,等.左西孟旦联合诺欣妥对急诊经皮冠脉介入治疗术后患者肾素、血管紧张素Ⅱ和心功能的影响[J].中国医药科学,2021,11(13):72-75.[24]吴群玫,梁秀娟,王霞,等.重组人脑利钠肽与左西孟旦应用于AMI急诊PCI患者的疗效与安全性[J].心血管康复医学杂志,2019,28(1):52-56.

相似文献/References:

[1]纪东华.卡托普利对冠心病介入治疗患者心室重构及炎性因子的影响[J].医学信息,2019,32(17):137.[doi:10.3969/j.issn.1006-1959.2019.17.045]
　JI Dong-hua.Effects of Captopril on Ventricular Remodeling and Inflammatory Factors in Patients with Coronary Heart Disease Undergoing Interventional Therapy[J].Journal of Medical Information,2019,32(23):137.[doi:10.3969/j.issn.1006-1959.2019.17.045]
[2]王建强,刘 瑜,张牧秋,等.房颤伴ACS患者经皮冠状动脉介入术后抗栓研究[J].医学信息,2019,32(14):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
　WANG Jian-qiang,LIU Yu,ZHANG Mu-qiu,et al.Study on Antithrombotic after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and ACS[J].Journal of Medical Information,2019,32(23):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
[3]张永满.房颤伴冠心病患者PCI术后抗栓治疗研究[J].医学信息,2020,33(04):66.[doi:10.3969/j.issn.1006-1959.2020.04.020]
　ZHANG Yong-man.Antithrombotic Therapy for Patients with Atrial Fibrillation and Coronary Heart Disease After PCI[J].Journal of Medical Information,2020,33(23):66.[doi:10.3969/j.issn.1006-1959.2020.04.020]
[4]贾俏红.不同院前急救模式对急性ST段抬高型心肌梗死的救治效果[J].医学信息,2021,34(09):134.[doi:10.3969/j.issn.1006-1959.2021.09.036]
　JIA Qiao-hong.The Effect of Different Pre-hospital Emergency Treatment Modes on Acute ST-segment Elevation Myocardial Infarction[J].Journal of Medical Information,2021,34(23):134.[doi:10.3969/j.issn.1006-1959.2021.09.036]
[5]高 珍,覃 辉.经皮冠状动脉介入术后造影剂诱导急性肾损伤预测模型的构建[J].医学信息,2021,34(16):87.[doi:10.3969/j.issn.1006-1959.2021.16.023]
　GAO Zhen,QIN Hui.Construction of A Predictive Model of Contrast Agent-induced Acute Kidney Injury After Percutaneous Coronary Intervention[J].Journal of Medical Information,2021,34(23):87.[doi:10.3969/j.issn.1006-1959.2021.16.023]
[6]巫 菲,薛奋龙,陈洪磊,等.左西孟旦与米力农在心脏瓣膜置换术围术期的心肌保护作用[J].医学信息,2021,34(16):128.[doi:10.3969/j.issn.1006-1959.2021.16.035]
　WU Fei,XUE Fen-long,CHEN Hong-lei,et al.Myocardial Protection of Levosimendan and Milrinone During the Perioperative Period of Heart Valve Replacement[J].Journal of Medical Information,2021,34(23):128.[doi:10.3969/j.issn.1006-1959.2021.16.035]
[7]田跃雷,李春彦.丹参多酚酸盐对急诊PCI患者术后氧化应激、心功能、血管内皮功能的影响[J].医学信息,2022,35(04):156.[doi:10.3969/j.issn.1006-1959.2022.04.041]
　TIAN Yue-lei,LI Chun-yan.Effect of Salvianolate on Oxidative Stress, Cardiac Function and Vascular Endothelial Functionin Patients After Emergency PCI[J].Journal of Medical Information,2022,35(23):156.[doi:10.3969/j.issn.1006-1959.2022.04.041]
[8]纪 翔.互联网联合心脏康复延续性护理对冠心病经皮冠状动脉介入术后康复效果的影响[J].医学信息,2022,35(10):186.[doi:10.3969/j.issn.1006-1959.2022.10.049]
　JI Xiang.Effect of Internet Combined with Continuous Cardiac Rehabilitation Nursing on Rehabilitation of Coronary Heart Disease After Percutaneous Coronary Intervention[J].Journal of Medical Information,2022,35(23):186.[doi:10.3969/j.issn.1006-1959.2022.10.049]
[9]李艳艳,陈 霞.早期心脏康复护理配合经皮冠状动脉介入术对急性心肌梗死患者康复效果的影响[J].医学信息,2023,36(11):157.[doi:10.3969/j.issn.1006-1959.2023.11.033]
　LI Yan-yan,CHEN Xia.Effect of Early Cardiac Rehabilitation Nursing Combined with Percutaneous Coronary Intervention on Rehabilitation of Patients with Acute Myocardial Infarction[J].Journal of Medical Information,2023,36(23):157.[doi:10.3969/j.issn.1006-1959.2023.11.033]
[10]董 菁,杨 雪,马文杰.信息化延续护理对冠心病PCI术后患者的服药依从性及相关知识水平的影响[J].医学信息,2023,36(17):176.[doi:10.3969/j.issn.1006-1959.2023.17.038]
　DONG Jing,YANG Xue,MA Wen-jie.Effect of Information-based Continuous Nursing on Medication Compliance and Related Knowledge Level of Patients with Coronary Heart Disease After PCI[J].Journal of Medical Information,2023,36(23):176.[doi:10.3969/j.issn.1006-1959.2023.17.038]

更新日期/Last Update: 1900-01-01